Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?

Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned that spending will jump.

24/7 Wall Street • 12 hours ago

Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Beyond analysts' top-and-bottom-line estimates for Amgen (AMGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

Zacks Investment Research • 7 hours ago

AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS

THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial markets.

PRNewsWire • Oct 28, 2026

Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?

Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.

Zacks Investment Research • Oct 28, 2026

Amgen: A Biotech Bargain Heading Into Q3 Earnings

On November 3, Amgen Inc. will report its results for Q3. As a reminder, its Q2 non-GAAP EPS rose 25.8% quarter-on-quarter to $6.29, primarily due to the strong performance of biosimilars, Blincyto, and Repatha. On October 24, Amgen released promising results from the DeLLphi-305 study evaluating Imdelltra+Imfinzi in the treatment of extensive-stage small-cell lung cancer.

Seeking Alpha • Oct 27, 2026

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 27, 2026

AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026

Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in IgG4-Related Disease and Real-World Evidence for KRYSTEXXA and TAVNEOS Further Highlight Amgen's Broad Portfolio and Commitment to People Living with Rare Diseases THOUSAND OAKS, Calif., Oct. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to present new data across its portfolio, including in rare and other serious autoimmune diseases at the American College of Rheumatology (ACR) Convergence 2026.

PRNewsWire • Oct 27, 2026

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net margin of 33.1%.

The Motley Fool • Oct 27, 2026

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue

Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen demonstrated moderate quarter-over-quarter revenue fluctuations, while Vertex Pharmaceuticals maintained a very steady and gradual upward revenue trend.

The Motley Fool • Oct 27, 2026

AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS

THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of David W.

PRNewsWire • Oct 26, 2026